Skip to content
← Childhood Ependymoma

HEALTH PROFESSIONAL · SOURCE READING

Treatment Option Overview for Childhood Ependymoma

Source: Childhood Ependymoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: January 6, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Many of the improvements in survival in patients with childhood cancer have been made as a result of clinical trials that have attempted to improve on the best available, accepted therapy. Clinical trials in pediatrics are designed to compare new therapy with therapy that is currently accepted as standard. This comparison may be done in a randomized study of two treatment arms or by evaluating a single new treatment and comparing the results with those previously obtained with existing therapy.

Because of the relative rarity of cancer in children, all patients with aggressive brain tumors should be considered for entry into a clinical trial. To determine and implement optimum treatment, review of each case by a multidisciplinary team of cancer specialists who have experience treating childhood brain tumors is required. Radiation therapy for pediatric brain tumors is technically demanding and should be performed in centers that have pediatric experience to ensure optimal results.

Treatment of childhood ependymoma begins with surgery. The type of adjuvant therapy given, such as a second surgery, chemotherapy, or radiation therapy, depends on the following:

Subtype of ependymoma.

Location of the tumor.

Whether the tumor was completely removed during the initial surgery.

Whether the tumor has disseminated throughout the central nervous system.

Child's age.

Table 1 describes the standard treatment options for newly diagnosed and recurrent childhood ependymoma.

Source links and citations
Table 1. Standard Treatment Options for Childhood Ependymoma
Treatment GroupStandard Treatment Options
WHO = World Health Organization.
Newly diagnosed childhood myxopapillary ependymoma (WHO grade 2)Surgery with or without adjuvant radiation therapy
Newly diagnosed childhood nonmyxopapillary spinal ependymomaSurgery
Radiation therapy
Newly diagnosed childhood intracranial (supratentorial or posterior fossa) ependymoma:Surgery
Adjuvant therapy:
No residual disease, no disseminated disease—Radiation therapy
Residual disease, no disseminated disease—Second-look surgery
—Radiation therapy
—Preirradiation chemotherapy
Central nervous system disseminated disease—Radiation therapy (not considered standard treatment)
—Chemotherapy (not considered standard treatment)
Children younger than 1 year—Chemotherapy
—Deferred radiation therapy
Recurrent childhood ependymomaSurgery
Radiation therapy and/or chemotherapy
Source links and citations

Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[1-3] Childhood and adolescent cancer survivors require close monitoring because cancer therapy side effects may persist or develop months or years after treatment. For specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice